Cardiff Oncology, Inc. (CRDF) — Analyst outlook / Analyst consensus target is. Based on 12 analyst ratings, the consensus is bullish — 8 Buy, 3 Hold, 1 Sell.
Analysts estimate Earnings Per Share (EPS) of $-0.99 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.95 vs est $-0.99 (beat +3.9%). 2025: actual $-0.69 vs est $-0.77 (beat +10.2%). Analyst accuracy: 92%.
CRDF Analyst Ratings
Buy
Based on 12 analysts giving stock ratings to Cardiff Oncology, Inc. in the past 3 months
EPS Estimates — CRDF
92%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$0.95
vs Est –$0.99
▲ 4.0% off
2025
Actual –$0.69
vs Est –$0.77
▲ 11.3% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — CRDF
84%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.001B
vs Est $0.001B
▲ 8.6% off
2025
Actual $0.001B
vs Est $0.000B
▲ 23.3% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
